USP44, ZNF454, and GPRC5B ctDNA Methylation Markers in Breast Cancer: Limited Clinical Relevance for Disease Monitoring and Tumor Characteristics.

IF 1.6 4区医学 Q4 ONCOLOGY

Asia-Pacific journal of clinical oncology Pub Date : 2025-09-08 DOI:10.1111/ajco.70015

Young Ju Jeong, Chang-Ho Jeon, Hoon Kyu Oh, Jeong Kyu Kim, Chun-Seok Yang, Na-Rang Lee, Doyeon Kim

{"title":"USP44, ZNF454, and GPRC5B ctDNA Methylation Markers in Breast Cancer: Limited Clinical Relevance for Disease Monitoring and Tumor Characteristics.","authors":"Young Ju Jeong, Chang-Ho Jeon, Hoon Kyu Oh, Jeong Kyu Kim, Chun-Seok Yang, Na-Rang Lee, Doyeon Kim","doi":"10.1111/ajco.70015","DOIUrl":null,"url":null,"abstract":"Purpose: This study aimed to identify breast cancer-specific circulating tumor DNA (ctDNA) methylation markers that correspond to tissue DNA methylation.Methods: Using The Cancer Genome Atlas (TCGA) database, we selected breast cancer-specific DNA methylation markers. The methylation and expression patterns of candidate genes were analyzed in breast cancer cell lines and tissue samples. We also assessed the methylation status in ctDNA obtained from breast cancer patients and examined associations with the clinicopathological features.Results: Among candidate genes with breast cancer-specific methylation patterns, USP44, ZNF454, and GPRC5B were selected. The methylation status and expression of selected genes varied by molecular subtype of cancer in the cell line. In tissue samples, expression of all three genes was generally lower in breast cancer than in controls. ctDNA methylation patterns showed no significant change before and after treatment for each candidate gene. Correlations between gene expression and DNA methylation status or clinicopathological characteristics in cancer tissues differed among genes.Conclusion: Further studies are needed for clinical application of liquid biopsy using methylation analysis for ctDNA according to individual characteristics for breast cancer.","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia-Pacific journal of clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ajco.70015","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study aimed to identify breast cancer-specific circulating tumor DNA (ctDNA) methylation markers that correspond to tissue DNA methylation.

Methods: Using The Cancer Genome Atlas (TCGA) database, we selected breast cancer-specific DNA methylation markers. The methylation and expression patterns of candidate genes were analyzed in breast cancer cell lines and tissue samples. We also assessed the methylation status in ctDNA obtained from breast cancer patients and examined associations with the clinicopathological features.

Results: Among candidate genes with breast cancer-specific methylation patterns, USP44, ZNF454, and GPRC5B were selected. The methylation status and expression of selected genes varied by molecular subtype of cancer in the cell line. In tissue samples, expression of all three genes was generally lower in breast cancer than in controls. ctDNA methylation patterns showed no significant change before and after treatment for each candidate gene. Correlations between gene expression and DNA methylation status or clinicopathological characteristics in cancer tissues differed among genes.

Conclusion: Further studies are needed for clinical application of liquid biopsy using methylation analysis for ctDNA according to individual characteristics for breast cancer.

查看原文本刊更多论文

乳腺癌中的USP44、ZNF454和GPRC5B ctDNA甲基化标记：与疾病监测和肿瘤特征的有限临床相关性

目的：本研究旨在鉴定与组织DNA甲基化相对应的乳腺癌特异性循环肿瘤DNA （ctDNA）甲基化标记。方法：利用癌症基因组图谱（TCGA）数据库，选择乳腺癌特异性DNA甲基化标记。分析了候选基因在乳腺癌细胞系和组织样本中的甲基化和表达模式。我们还评估了从乳腺癌患者获得的ctDNA的甲基化状态，并检查了与临床病理特征的关联。结果：在具有乳腺癌特异性甲基化模式的候选基因中，选择了USP44、ZNF454和GPRC5B。甲基化状态和所选基因的表达因癌细胞的分子亚型而异。在组织样本中，这三种基因在乳腺癌中的表达通常低于对照组。每个候选基因的ctDNA甲基化模式在治疗前后没有显着变化。基因表达与肿瘤组织中DNA甲基化状态或临床病理特征之间的相关性因基因而异。结论：根据乳腺癌个体特点，ctDNA甲基化分析液体活检的临床应用有待进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asia-Pacific journal of clinical oncology 医学-肿瘤学

CiteScore

3.40

自引率

0.00%

发文量

175

审稿时长

6-12 weeks

期刊介绍： Asia–Pacific Journal of Clinical Oncology is a multidisciplinary journal of oncology that aims to be a forum for facilitating collaboration and exchanging information on what is happening in different countries of the Asia–Pacific region in relation to cancer treatment and care. The Journal is ideally positioned to receive publications that deal with diversity in cancer behavior, management and outcome related to ethnic, cultural, economic and other differences between populations. In addition to original articles, the Journal publishes reviews, editorials, letters to the Editor and short communications. Case reports are generally not considered for publication, only exceptional papers in which Editors find extraordinary oncological value may be considered for review. The Journal encourages clinical studies, particularly prospectively designed clinical trials.